When Drug Trials Are Halted.
When significant safety questions arise during a trial, the FDA has the option to place a full or partial clinical hold on treatment and new enrollment. Clinical holds are designed to protect patients from serious harm but they can also cause expensive delays for drug developers and frustrations for patients. While some problems can be resolved quickly, others can permanently derail a drug's development.
D001402:B-Lymphocytes / Q000187:drug effects; D064987:Cell- and Tissue-Based Therapy / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D011948:Receptors, Antigen, T-Cell / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D011948:Receptors, Antigen, T-Cell